Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UnitedHealthcare Coverage Policy Undercutting Neulasta Biosimilars Draws Concerns

Executive Summary

US insurer’s commercial plans will favor the originator drug over biosimilars in return for a price concession from Amgen, while UnitedHealthcare’s Medicare Advantage plans will prefer biosimilars in several categories.

You may also be interested in...



Amgen's US Biosimilar Launches Are Off To A Steady Start, With A Big Coverage Decision

United HealthCare agreed to cover Mvasi and Kanjinti in a preferred position. Amgen VP-oncology sales & marketing Susan Logan talked to Scrip about the company's first US biosimilar launches.

Amgen’s Nonconformist Position On Biosimilar Payment Policy Reflects Market Strategy

Company objects to legislative proposals that would enhance Medicare Part B reimbursement for biosimilars to boost uptake, even as it launches its first biosimilars in the US market.

Coherus Chief: FTC Must Probe Originators’ Anti-Competitive Tactics

Bundled rebate contracts for biologic brands that are designed to thwart biosimilar competition in the US are anti-competitive practices that deserve Federal Trade Commission action, biosimilar developer Coherus’ chief argues in a newspaper opinion piece.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS125426

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel